Friday, 01 October 2021 09:50

Anticoagulation news items. Week commencing 27th September 2021

Thromboprophylaxis for children post‐Fontan procedure: Insights From the UNIVERSE Study

Journal of the American Medical Association
RCT (n=112) found that compared to aspirin, rivaroxaban liquid based on body weight–adjusted dosing had similar safety profile (clinically relevant non-major bleeding in 6% vs 9% on aspirin) & fewer thrombotic events (2% vs 9%, respectively), albeit not statistically significant.

 

Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia

JAMA Neurology
Study of 116 cases of cerebral venous sinus thrombosis (CVST) after covid vaccine found 67.2% had thrombosis with thrombocytopenia syndrome (TTS). In hospital mortality rate was 47% with TTS, 5% without TTS and 3.9% in a control group of patients with CVST before the pandemic.

 

Revised SPC: Clexane (enoxaparin) Forte Syringes

electronic Medicines compendium
SPC has been revised to reflect licence extension covering extended treatment of DVT & PE & prevention of its recurrence in patients with active cancer. Recommended dose is 100 IU/kg (1 mg/kg) BD by SC injections for 5-10 days, followed by 150 IU/kg (1.5 mg/kg) OD up to 6 months.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services